Exact Sciences has expanded its collaboration with private insurer Humana to make the Cologuard Plus test available to eligible Humana Medicare Advantage members as an in-network service across the US.
This improves accessibility of patients to colorectal cancer (CRC) screening.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Cologuard Plus and Cologuard are said to be the non-invasive CRC screening alternatives for the adult population aged 45 years or above who are at average risk for the condition.
These tests are developed in partnership with Mayo Clinic.
Introduced in March 2025, the Cologuard Plus test has secured Medicare coverage and approval from the US Food and Drug Administration (FDA). It also aligns with the US Preventive Services Task Force guidelines.
According to the company, the Cologuard test identifies particular DNA markers and blood in stool that are linked to cancer and precancerous conditions.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSince its launch in 2014, Cologuard has been utilised more than 20 million times for CRC screening.
The Plus version introduces new biomarkers and enhanced laboratory processes. It is designed to minimise false positives by over 40% in comparison to its predecessor.
Exact Sciences Screening general manager and executive vice-president Jake Orville said: 鈥淭he Exact Sciences team is proud to expand access to Cologuard Plus through our collaboration with Humana, making it easier for more people to access this revolutionary, non-invasive colorectal cancer screening test from the comfort of home.
鈥淭his agreement reflects our shared commitment to removing barriers for patients and advancing earlier detection, when treatment is most effective.鈥�
The Cologuard test enables individuals to gather samples at their convenience in their own homes, without the need for any preparations or taking time away from work. Once the sample is collected, it can be sent back to the laboratory for analysis.
Both tests are exclusively available in the US.
In January 2025, Exact Sciences reported trial results of the Oncodetect test, intended to detect residual cancer cells post-treatment.
